Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Other ORP type
Data sources: ZENODO
addClaim

What is the recommended dose of Clexane (enoxaparin) for patients with atrial fibrillation who are nil by mouth?

Authors: Tripdatabase;

What is the recommended dose of Clexane (enoxaparin) for patients with atrial fibrillation who are nil by mouth?

Abstract

Specific dosing for enoxaparin in atrial fibrillation for nil by mouth patients typically follows therapeutic anticoagulation dosing, such as in deep vein thrombosis treatment, but may require individual adjustment based on patient factors.

Powered by OpenAIRE graph
Found an issue? Give us feedback